Nature communications, 2023-01, Vol.14 (1), p.333-333, Article 333
- Chew, Kara W.
- Moser, Carlee
- Daar, Eric S.
- Wohl, David A.
- Li, Jonathan Z.
- Coombs, Robert W.
- Ritz, Justin
- Giganti, Mark
- Javan, Arzhang Cyrus
- Li, Yijia
- Choudhary, Manish C.
- Deo, Rinki
- Malvestutto, Carlos
- Klekotka, Paul
- Price, Karen
- Nirula, Ajay
- Fischer, William
- Bala, Veenu
- Ribeiro, Ruy M.
- Perelson, Alan S.
- Fletcher, Courtney V.
- Eron, Joseph J.
- Currier, Judith S.
- Hughes, Michael D.
- Smith, Davey M.
2023
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Chew, Kara W.
- Moser, Carlee
- Daar, Eric S.
- Wohl, David A.
- Li, Jonathan Z.
- Coombs, Robert W.
- Ritz, Justin
- Giganti, Mark
- Javan, Arzhang Cyrus
- Li, Yijia
- Choudhary, Manish C.
- Deo, Rinki
- Malvestutto, Carlos
- Klekotka, Paul
- Price, Karen
- Nirula, Ajay
- Fischer, William
- Bala, Veenu
- Ribeiro, Ruy M.
- Perelson, Alan S.
- Fletcher, Courtney V.
- Eron, Joseph J.
- Currier, Judith S.
- Hughes, Michael D.
- Smith, Davey M.
- Titel
- Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
- Ist Teil von
- Nature communications, 2023-01, Vol.14 (1), p.333-333, Article 333
- Ort / Verlag
- London: Nature Publishing Group UK
- Erscheinungsjahr
- 2023
- Quelle
- Alma/SFX Local Collection
- Sprache
- Englisch
- Identifikatoren
- ISSN: 2041-1723eISSN: 2041-1723DOI: 10.1038/s41467-023-35835-3Titel-ID: cdi_doaj_primary_oai_doaj_org_article_855e78e2e14745259e95ef61051904bc